The FDA’s gag rule on off-label treatments

Michael Cannon, director of health policy studies for the Cato Institute, talks about the gag rule that places restrictions on discussing legal uses of drugs for off-label purposes, as well as a bill that would make trial drugs available to terminally ill patients.